Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study
HTML-код
- Опубликовано: 21 окт 2023
- Dr. Filippo Pietrantonio reports on key results from ESMO Congress 2023 on LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase 3 study.
Simultaneous publication in the NEJM: www.nejm.org/doi/full/10.1056...
Produced by the European Society for Medical Oncology
oncologypro.esmo.org Наука